Wegovy 7.2mg: Everything you need to know about the new higher dose

Wegovy 7.2mg is a newer strength of the weight loss injection semaglutide. Developed by Novo Nordisk, this is intended to help patients who have plateaued on the current maximum dose of 2.4mg

In STEP UP clinical trials, this new dose demonstrated an average weight loss of 20.7% over 72 weeks. This makes the new dose a significant advancement for those seeking enhanced weight loss support.

At Quick Meds, we're committed to keeping our patients informed about the latest developments in weight loss treatment. Here's everything you need to know about Wegovy 7.2mg, including when it might become available in the UK.

What is Wegovy 7.2mg?

Wegovy is a weight loss treatment containing the active ingredient semaglutide. As a GLP-1 agonist, semaglutide works by reducing appetite and helping you feel fuller for longer. The medication is administered as a once-weekly subcutaneous injection and is only available on prescription.

The current maximum approved dose of Wegovy is 2.4mg. Whilst many patients achieve significant results at this dose, some find their journey stalls over time. The newer dose has been developed specifically to address this challenge, offering a higher dose option for those who need additional support to continue to benefit from treatment.

The manufacturer Novo Nordisk has submitted an application for European Medicines Agency (EMA) approval in July 2025. Once approved, the higher dose can be used to help patients already established on Wegovy.

How Effective is Wegovy 7.2mg? STEP UP Trial Results

The STEP UP clinical trial compared the effectiveness of the new dose with the current maximum dose, 2.4mg. This trial, conducted over 72 weeks in more than 1,400 adults demonstrated a meaningful improvement over the current maximum dose.

Weight Loss Comparison: 7.2mg vs 2.4mg

The results show the new 7.2mg dose doubles the likelihood of achieving 25% weight loss compared to the 2.4mg dose. For a patient weighing 100kg (approximately 15 stone 10 pounds), this could mean losing over 20kg rather than 17.5kg.

It's worth noting that in the trial, patients escalated directly from 2.4mg to 7.2mg without intermediary doses. This was designed to compare the effectiveness of the new dose directly against the current maximum.

Wegovy 7.2mg vs Mounjaro: How Do They Compare?

With Mounjaro (tirzepatide) currently being the market leader for weight loss, many patients want to understand how the new Wegovy dose compares.

The SURMOUNT-5 trial trial compared the highest dose of Mounjaro (15mg) against Wegovy 2.4mg, with Mounjaro achieving 20.2% weight loss compared to 13.7% for Wegovy 2.4mg. This established Mounjaro as the more effective option at those doses.

However, the STEP UP trial results change this picture. Wegovy 7.2mg achieved 20.7% weight loss, which is comparable to and slightly exceeds Mounjaro's 20.2% result. While these medications haven't been compared head-to-head at these doses, the independent trial data suggests similar effectiveness.

Key Differences Between Wegovy 7.2mg and Mounjaro 15mg

For patients already established on Wegovy but have plateaued, the 7.2mg dose offers an opportunity to reinvigorate their weight loss journey without switching to a different medication. This continuity may be particularly valuable for those who tolerate Wegovy well.

Who is Eligible for Wegovy 7.2mg?

Eligibility for Wegovy 7.2mg is expected to follow the same criteria as other doses, with additional requirements specific to this higher strength.

Basic Eligibility Criteria

To be prescribed Wegovy, you must meet one of these criteria alongside making sustainable lifestyle changes:

• BMI of 30 or above (classified as obesity), or

• BMI of 27 or above with at least one weight-related health condition such as type 2 diabetes, high blood pressure, or high cholesterol

Specific Requirements for the 7.2mg Dose

The 7.2mg dose is not a starting point. To receive Wegovy 7.2mg, you must:

Already be taking Wegovy 2.4mg

Be tolerating the 2.4mg dose well with minimal side effects

Have reached a plateau in your weight loss or require additional support to meet your goals

You cannot start Wegovy treatment at the 7.2mg dose, and you cannot switch directly from other weight loss medications such as Mounjaro or Saxenda to Wegovy 7.2mg.

The Dose Escalation Journey

All Wegovy patients follow a gradual dose escalation schedule to minimise side effects:

1. Weeks 1–4: 0.25mg once weekly

2. Weeks 5–8: 0.5mg once weekly

3. Weeks 9–12: 1mg once weekly

4. Weeks 13–16: 1.7mg once weekly

5. Week 17 onwards: 2.4mg once weekly (current maximum)

6. Future option: 7.2mg once weekly (once approved)

Each increase occurs every four weeks, allowing your body to adjust gradually. Our pharmacists work closely with patients throughout this process to ensure safe and effective treatment.

Wegovy 7.2mg Side Effects: What to Expect

The side effects of Wegovy 7.2mg are similar to those seen with other doses in the Wegovy range. However, clinical trial data shows they occur slightly more frequently at the higher dose.

Gastrointestinal Side Effects

In the STEP UP trial, gastrointestinal adverse events were reported by 70.8% of patients taking 7.2mg compared to 61.2% of those on 2.4mg. The most common include:

• Nausea

• Vomiting

• Diarrhoea

• Constipation

• Abdominal pain or discomfort

• Bloating

These side effects are more likely to occur when starting treatment and when increasing the dose. They usually improve as your body adjusts to the medication.

Other Common Side Effects

• Headache

• Fatigue

• Dizziness

• Injection site reactions

Serious Side Effects (Rare)

While uncommon, more serious side effects can occur and require immediate medical attention:

• Gallstones: Signs include severe abdominal pain, particularly in the upper right area

• Acute pancreatitis: Symptoms include severe abdominal pain that radiates to the back, along with nausea and vomiting

• Severe allergic reactions: Including difficulty breathing, swelling of the face or throat, and severe rash

• Kidney problems: Particularly in those with existing kidney conditions

The gradual dose escalation approach helps minimise side effects by allowing your body time to adjust at each stage.

When Will Wegovy 7.2mg Be Available in the UK?

Wegovy 7.2mg is now available in the UK. This dose now has regulatory approval.

Current Status

Novo Nordisk submitted an application for EMA (European Medicines Agency) approval in July 2025. The EMA has now approved the higher 7.2mg dose after a thorough review of clinical trial data confirming safety and efficacy.

What This Means for You

If you're currently taking Wegovy: Once you have progressed through the dose escalation pathway and have remained on the 2.4mg for 4 weeks you can then increase your dose to 7.2mg.

If you're new to Wegovy: Starting treatment now means you'll progress through the dose escalation schedule and depending on your weight loss goals and tolerability can increase your dose every 4 weeks.

How to take Wegovy 7.2mg dose

Currently there is no 7.2mg pen available. To administer a 7.2mg dose, three doses of 2.4mg should be administered to make up the full dose.

This will change once the new 7.2mg device becomes available.

To administer a 7.2mg dose, 3 needles are required to administer 3 separate injections of 2.4mg. Please note:

1. A new needle should be used for each injection.

2. The doses must be administered into the same body area but at least 5cm apart.

3. The doses must be administered at the same time - i.e. immediately one after the other.

Do not spread the dose out over time/days. The dose should be administered in its entirety once weekly, at the same time.

How Much Will Wegovy 7.2mg Cost?

Official pricing for Wegovy 7.2mg is £399.95. The cost is more than the current 2.4mg dose for several reasons:

• Higher quantity of active ingredient per dose

• Increased manufacturing costs

• Premium positioning as an enhanced treatment option

How to Get Wegovy 7.2mg from Quick Meds

Quick Meds is a GPhC-registered online pharmacy committed to supporting patients throughout their weight loss journey.

For Current Wegovy Patients

If you're already taking Wegovy from Quick Meds, you don't need to take any action. Our pharmacists monitor patient progress and will contact eligible patients as soon as the 7.2mg dose is approved and available. We'll review your treatment history and discuss whether the higher dose is appropriate for your individual needs.

For New Patients

If you haven't started Wegovy yet, now is an excellent time to begin your weight loss journey. Starting today means you'll complete the necessary dose escalation.

To start treatment, you'll need to:

1. Complete our online consultation

2. Have your information reviewed by our prescribers

3. If approved, receive your medication delivered to your door

4. Begin your dose escalation under our clinical guidance

START YOUR WEGOVY CONSULTATION

Summary

Wegovy 7.2mg represents an important advancement in weight loss treatment, offering patients who have plateaued on the 2.4mg dose an opportunity to achieve enhanced results. With the STEP UP trial demonstrating 20.7% average weight loss over 72 weeks, this new dose puts Wegovy on par with the best-performing weight loss medications currently available.

Quick Meds remains committed to providing the highest standard of weight loss support to our patients. Whether you're currently on Wegovy or considering starting treatment, our GPhC-registered pharmacists are here to guide you every step of the way.